Mequitazine
 | This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: Convert long prose list(s) to bulleted list(s). (March 2021) |
 | |
| Clinical data | |
|---|---|
| Trade names | Primalan |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Mequitazine (trade name Primalan) is an
.It was patented in 1969 and came into medical use in 1976.[2]
Contraindications
Severe liver disease; premature infants or full-term neonates.
Special precautions
Pregnancy, lactation; severe cardiovascular disorders; asthma; angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction; renal and hepatic impairment; elderly, children; epilepsy. May impair ability to drive or operate machinery.
Adverse reactions
CNS depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. Headache, psychomotor impairment and antimuscarinic effects. Rarely, rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, confusion, sleep and GI disturbances, tinnitus, hypotension, hair loss. Photosensitivity, jaundice.
Drug interactions
Enhances effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Can mask signs of ototoxicity caused by aminoglycosides. QT prolongation (which can lead to torsades de pointes arrhythmia) reported with spiramycin.
Synthesis
Same precursor as for Quifenadine. Note that the synthesis has changed over the years from the original. One route seems to involve a Johnson–Corey–Chaykovsky reaction of the starting ketone, although another secondary route is also discussed.
References
- ^ "Active substance: mequitazine" (PDF). List of nationally authorised medicinal products. Amsterdam: European Medicines Agency. 15 October 2020.
- ISBN 9783527607495.
- ^ US 4546185, Bondiou JC, Hodac F, Legroux D, issued Pharmuka Laboratoires
- PMID 19881287.
- .
- PMID 21657243.
Further reading
- Ramírez Chanona N, del Rio Navarro BE, Pérez Martín J (November–December 2005). "[Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience]". Revista Alergia Mexico (in Spanish). 52 (6): 221–225. PMID 16568706.
- Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG (February 2004). "A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo". Clinical and Experimental Allergy. 34 (2): 250–258. S2CID 23019669.
- Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, et al. (February 1998). "Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 284 (2): 437–442. PMID 9454781.
- Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J (April 1997). "Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis". Allergy. 52 (4): 451–454. S2CID 34785561.
External links
- "Mequitazine". Drug Information Portal. U.S. National Library of Medicine.
